LDHA and neoplasm: Oxamate, as an LDHA inhibitor, is able to reprogram glucose metabolism in cancer stem cells, reduce histone H3K18 lactate levels, and inhibit lactate production alter the phenotype of tumor-infiltrating car-t cells in animal models, and mitigate immunosuppression of the tumor microenvironment.